Key result
SBK2 overexpression attenuates cardiac hypertrophy and preserves systolic function by maintaining mitochondrial complex I integrity.
Why the study?
Impaired mitochondrial complex I activity drives pathological cardiac hypertrophy and heart failure, but its regulatory mechanisms are poorly understood.
Does SBK2 modulate cardiac hypertrophy and mitochondrial complex I function in experimental models?
Does SBK2 modulate cardiac hypertrophy and mitochondrial complex I function in experimental models?
SBK2 is identified as a novel upstream kinase that protects against pathological cardiac hypertrophy by phosphorylating NDUFV1 and preserving mitochondrial complex I function.
May support SBK2 as a target in experimental hypertrophy; leaves open translation to human disease.
BACKGROUND: Heart failure remains a major global health burden, driven largely by pathological cardiac hypertrophy. Mitochondrial dysfunction, particularly impaired mitochondrial complex I activity, is central to the disease progression, yet its regulatory mechanisms are poorly understood. Cross-species transcriptomic screening and UK Biobank analyses identified SBK2 (Src homology 3 domain-binding kinase 2) as a conserved, cardiac-enriched kinase potentially linked to heart failure risk. We hypothesized that SBK2 regulates cardiac hypertrophy by modulating mitochondrial complex I function. METHODS: Cross-species conserved genes were identified from Gene Expression Omnibus (GEO) data sets, and variants within ±10 kb of SBK2, ADAMTSL2 (ADAMTS-like protein 2), LOX (lysyl oxidase), and SPP1 (secreted phosphoprotein 1) were assessed for heart failure association in the UK Biobank cohort. SBK2 expression was examined in experimental models and publicly available human hypertrophic cardiomyopathy data sets, and its function was investigated through loss- and gain-of-function studies in cardiomyocytes and mice. The substrates and interacting partners of SBK2 were identified by proteomic and interactome analyses and validated by in vitro kinase assays and coimmunoprecipitation. Mitochondrial protein import and respiratory supercomplex assembly were assessed by biochemical fractionation and blue native PAGE. RESULTS: SBK2 expression was reduced in hypertrophic hearts and primary neonatal rat ventricular myocytes. Cardiomyocyte-specific overexpression of SBK2 attenuated hypertrophy and fibrosis, improved systolic function, and suppressed maladaptive gene expression. Conversely, SBK2 knockdown exacerbated these phenotypes. Mechanistically, SBK2 directly bound and phosphorylated NDUFV1 (NADH: ubiquinone oxidoreductase core subunit V1) at serine 251. This modification enhanced the interaction between NDUFV1 and the cytosolic chaperone HSPA1A (heat shock protein family A [Hsp70] member 1A) and facilitated TOM70 (translocase of outer mitochondrial membrane 70)-dependent mitochondrial import. Increased mitochondrial NDUFV1 promoted complex I activity, respiratory supercomplex assembly, oxidative phosphorylation, mitochondrial fusion, and redox homeostasis. Pharmacological inhibition of complex I or NDUFV1 silencing abolished SBK2-mediated protection. Moreover, a phospho-deficient NDUFV1 mutant (S251A) failed to rescue hypertrophic phenotypes in SBK2-deficient cardiomyocytes. CONCLUSIONS: SBK2 is an upstream kinase that couples cytosolic signaling to mitochondrial protein import by phosphorylating NDUFV1, thereby sustaining complex I integrity and mitochondrial function to restrain pathological cardiac hypertrophy. These findings uncover a previously unrecognized SBK2-NDUFV1 signaling axis linking kinase signaling to mitochondrial proteostasis and identify a potential therapeutic target for heart failure.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied Heart failure and cardiac hypertrophy. SBK2 modulation vs. Control was evaluated on Cardiac hypertrophy, fibrosis, and systolic function. Cardiomyocyte-specific overexpression of SBK2 attenuated hypertrophy and fibrosis and improved systolic function by phosphorylating NDUFV1 and sustaining mitochondrial complex I integrity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: